Pharvaris publishes study validating patient outcomes in hereditary angioedema
Go back to Pharvaris publishes study validating patient outcomes in hereditary angioedema| (NASDAQ: PHVS) | Delayed: 34.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.01 | 52 Week High | $ | |||
| Open | $34.01 | 52 Week Low | $ | |||
| Day High | $34.01 | P/E | N/A | |||
| Day Low | $34.01 | EPS | $ | |||
| Volume | 1 | |||||
